ChartMill · Sep 4, 2026
The trading volume of these stocks is deviating from the norm in today's session.
Unusual volume stocks are being observed in Friday's session.
NASDAQ · BTAI
BioXcel Therapeutics, Inc.
Healthcare · Biotechnology
$0.07
Up+$0.00 (+0.00%)
Updated Sep 16, 2026, 10:28 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 45.49M
- P/E ratio
- -0.32
- Dividend yield
- 0.00%
- 52-week range
- $0.07 – $4.29
- Volume
- 47.48M
- Avg. volume
- 961.53K
Price performance
BTAI price history
1M range · 14 trading sessions · Daily adjusted prices
BTAI closed at $0.07 after 14 trading sessions, down 90.67% for the selected period.
- Last close
- $0.07
- Period change
- -90.67%
- Period low
- $0.07
- Period high
- $0.83
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $0.0927 | $0.0935 | $0.069 | $0.0739 | 47.48M |
| Sep 3, 2026 | $0.1201 | $0.1272 | $0.11 | $0.1175 | 151M |
| Sep 2, 2026 | $0.13 | $0.197 | $0.1055 | $0.107 | 46.79M |
| Sep 1, 2026 | $0.14 | $0.1416 | $0.12 | $0.137 | 15.69M |
| Aug 31, 2026 | $0.1509 | $0.17 | $0.1415 | $0.1628 | 10.78M |
| Aug 28, 2026 | $0.224 | $0.2299 | $0.1569 | $0.1814 | 58.56M |
| Aug 27, 2026 | $0.7492 | $0.7632 | $0.7001 | $0.7188 | 1.08M |
| Aug 26, 2026 | $0.758 | $0.7853 | $0.7364 | $0.78 | 902.2K |
| Aug 25, 2026 | $0.7829 | $0.8113 | $0.711 | $0.7422 | 1.58M |
| Aug 24, 2026 | $0.80 | $0.833 | $0.751 | $0.7606 | 1.12M |
| Aug 21, 2026 | $0.81 | $0.859 | $0.792 | $0.8038 | 1.24M |
| Aug 20, 2026 | $0.84 | $0.84 | $0.7979 | $0.7985 | 902.32K |
| Aug 19, 2026 | $0.79 | $0.8637 | $0.79 | $0.8274 | 797.61K |
| Aug 18, 2026 | $0.85 | $0.8955 | $0.7801 | $0.7921 | 1.85M |
Latest BTAI news
The latest Smart Investors Daily articles mentioning BTAI.
Stock researchCompany · Overview
BTAI research
Overview
Company profile and research snapshot.
Company profile
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $12.00
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 2, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 17, 2026 | Rodman & Renshaw | Buy | — |
| Mar 5, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 15, 2025 | HC Wainwright & Co. | Buy | — |
| Sep 12, 2025 | Mizuho | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 6, 2026
BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of +25.00% and +7.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Benzinga · Jul 15, 2026
BigBear.ai Introduces New Capabilities To Offer Flexibility To U.S. Department Of War Mission Team For Generative AI
BigBear.ai (NYSE:BBAI), a specialized defense and security technology company providing mission-ready AI, today announced a significant expansion of its generative AI platform, introducing new capabilities designed to
Benzinga · Mar 6, 2026
Why Are BioXcel Therapeutics Shares Down Friday?
BioXcel Therapeutics shares fall after a rally as BXCL501 Phase 2 data show promise for treating opioid withdrawal symptoms.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
